1. Which of the following hormones is increased in response to weight loss, driving further weight regain?

2. Which of the following biomarkers is improved or seen with as little as 5% weight loss?

3. What percent weight loss has been shown to result in remission of type 2 diabetes mellitus (T2DM)?

4. You are asked to see a 55-year-old woman with a body mass index (BMI) of 35.5 kg/m2. She has been trying to lose weight for the past year using diet and exercise, but her weight remains unchanged. She has a history of T2DM and hypertension. She currently takes metformin 1000 mg twice daily, lisinopril 20 mg once daily, and hydrochlorothiazide 12.5 mg once daily. Her glycated hemoglobin (A1C) is 7.9%, and her blood pressure is 149/96 mm Hg bilaterally. Which of the following would NOT be an appropriate pharmacologic treatment option for this patient to minimize her weight gain and/or promote weight loss?

5. Your patient underwent a Roux-en-Y gastric bypass 6 weeks ago and is experiencing daily vomiting. Which of the following nutritional deficiencies is this patient at greatest risk of developing?

6. Which of the following would be the BEST initial question when discussing weight with a patient?

7. A 46-year-old woman is referred to a registered dietitian from her primary care provider for weight management and dietary consultation. When discussing dietary management and weight loss with this patient, which of the following is the most important dietary approach to emphasize for weight loss?

8. You are asked to see a 45-year-old woman with a BMI of 35.5 kg/m2. She has been trying to lose weight for the past year using diet and exercise, but her weight remains unchanged. She has a history of T2DM, hypertension (HTN), intermittent diarrhea, and calcium oxalate kidney stones. She currently takes metformin 1000 mg twice daily, lisinopril 20 mg once daily, and hydrochlorothiazide 12.5 mg once daily. Her A1C is 7.9% and blood pressure is 149/96 mm Hg bilaterally. Which of the following would be the most appropriate pharmacologic treatment option for this patient?

9. Which of the following anti-obesity medications is FDA approved for treatment of adolescent obesity in patients ≥12 years old?

10. You are managing a patient for obesity with lifestyle modification and semaglutide 2.4 mg SQ once weekly. She has successfully lost 15% of her initial body weight over the past year. The patient is interested in getting off the medication. What can she expect once she stops the medication?

11. In the SCALE TEENS trial with liraglutide for adolescent patients with obesity, what percentage of patients had a BMI reduction of ≥5%?

12. In the SURMOUNT-1 trial, what was the mean percentage weight loss in patients with obesity receiving tirzepatide 15 mg SQ once weekly?

« Return to Activity